Clinical trials: Lymphoid Neoplasms
Chronic Lymphocytic Leukemia
A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to evaluate the efficacy of venetoclax monotherapy in participants with relapsed/refractory CLL with or without the 17p deletion or TP53 mutation, including those who have received prior treatment…
- Trial name
- VENICE I (NCT02756611)
- Testing
- Venetoclax
- Where
- 67 sites in United States, Austria and 19 more
- Volunteers
- 258 people
- Sponsor
- AbbVie
Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue
This is an open label, phase II study to evaluate the capacity of Rituximab (Mabthera®) plus Lenalidomide (Revlimid®) to induce objective responses in patients with Mucosa Associated Lymphoid Tissue (MALT) lymphoma presenting…
- Trial name
- NCT01611259
- Testing
- Rituximab and Lenalidomide
- Where
- 5 sites in Austria
- Volunteers
- 50 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Chronic Lymphocytic Leukemia (CLL), Leukaemia, Lymphocytic, Chronic
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
This is a Phase II, open label, single arm, multi-centre study investigating the safety and efficacy of ofatumumab plus bendamustine in subjects with untreated or relapsed CLL.
- Trial name
- NCT01520922
- Testing
- Ofatumumab, Bendamustine
- Where
- 33 sites in United States, Belgium and 6 more
- Volunteers
- 99 people
- Sponsor
- Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia, Non Hodgkins Lymphoma
T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
Subjects are being asked to participate in this study because treatment of their disease requires them to receive a stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Non Hodgkins Lymphoma, Myelodysplastic Syndrome, Acute Myeloid Leukemia
- Trial name
- MOHEL (NCT00368355)
- Testing
- Ara-C, Cyclophosphamide, Campath-1H
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Baylor College of Medicine
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
This phase II trial studies how well etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin (DA-EPOCH) works in treating patients with acute lymphoblastic leukemia or lymphoblastic lymphoma.
- Trial name
- NCT03023046
- Testing
- Cyclophosphamide, Dasatinib, Doxorubicin
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Washington
Leukaemia, Lymphocytic, Chronic
A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia
This is an open-label study to evaluate tolerability, safety, efficacy and pharmacokinetic profile of ofatumumab in combination with chlorambucil in Japanese patients with previously untreated Chronic Lymphocytic Leukemia (CLL).
- Trial name
- NCT01563055
- Testing
- chlorambucil, tablets, ofatumumab (GSK1841157) infusion
- Where
- 6 sites in Japan
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
The purpose of this study is to determine whether a repeat dose administration of ATIR101 is safe and effective when infused in patients with a hematologic malignancy following a T-cell depleted stem cell graft from a related…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT02500550
- Testing
- ATIR101, Haploidentical hematopoietic stem cell transplantation (HSCT), TBI regime
- Where
- 11 sites in Belgium, Canada and 4 more
- Volunteers
- 15 people
- Sponsor
- Kiadis Pharma
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
This phase II trial studies the side effects and how well blinatumomab and combination chemotherapy or dasatinib, prednisone, and blinatumomab work in treating older patients with acute lymphoblastic leukemia.
- Conditions
- Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent Acute Lymphoblastic Leukemia
- Trial name
- NCT02143414
- Testing
- Biopsy Procedure, Biospecimen Collection, Blinatumomab
- Where
- 195 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia
Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline
Primary Objective: To evaluate the efficacy (combined morphologic and flow remissions) of a combination of fludarabine, cyclophosphamide and multiple dose rituximab as frontline therapy for CLL.
- Trial name
- NCT00794820
- Testing
- Fludarabine Phosphate, Cyclophosphamide, Rituximab
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia
FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years
The goal of this clinical research study is to learn if using a combination of fludarabine, cyclophosphamide, and mitoxantrone plus rituximab, with the growth factor pegylated filgrastim, will improve the response to treatment…
- Trial name
- NCT00254410
- Testing
- Fludarabine, Cyclophosphamide, Mitoxantrone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
This study is testing the effectiveness of the study drug combination of acalabrutinib, umbralisib, and ublituximab in participants with Chronic Lymphocytic leukemia (CLL).
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT04624633
- Testing
- Acalabrutinib, Umbralisib, Ublituximab
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Jennifer R. Brown, MD, PhD
Hematologic Malignancies
Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies
The purpose of this study is to determine disease-free survival, overall survival, time to progression, regimen-related toxicity and/or treatment-related mortality in patients with hematologic malignancies treated with…
- Trial name
- NCT00741455
- Testing
- Stem Cell Transplant, G-CSF, Fludarabine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Adult T-Cell Lymphoma (ATL)
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)
Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, and efficacy of HBI-8000 40 mg BIW in patients with relapsed or refractory ATL (R/R ATL)
- Trial name
- NCT02955589
- Testing
- HBI-8000
- Where
- 15 sites in Japan
- Volunteers
- 23 people
- Sponsor
- HUYABIO International, LLC.
Lymphoid Leukemia, Acute Lymphoblastic Leukemia
Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia
This study involves Vyxeos (CPX-351), a formulation of a fixed combination of the two anti-tumor drugs, cytarabine and daunorubicin that will be given as an infusion over 90 minutes.
- Conditions
- Lymphoid Leukemia, Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
- Trial name
- NCT03575325
- Testing
- CPX-351
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-Hodgkin's Lymphoma, Cancer
Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach
1.1 To determine the efficacy of a combination treatment of VP-16, chlorambucil, dexamethasone, and vincristine in patients with relapsed/refractory hematological malignancies.
- Trial name
- NCT00250718
- Testing
- Vincristine, VP-16, Rituximab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- New Mexico Cancer Research Alliance
Follicular Lymphoma, Small Lymphocytic Lymphoma
A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
Despite strong evidence suggesting that vitamin D deficiency is associated with undesirable outcomes in patients with numerous cancers, there has never been a thorough study of vitamin D treatment in subjects undergoing treatment…
- Conditions
- Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Mucosal-Associated Lymphoid Tissue Lymphoma
- Trial name
- ILyAD (NCT03078855)
- Testing
- Vitamin D, Rituximab
- Where
- 7 sites in United States
- Volunteers
- 211 people
- Sponsor
- Jonathan Friedberg
Graft Versus Host Disease, Leukemia
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan
RATIONALE: Giving monoclonal antibody therapy, radioimmunotherapy, and chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's…
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00577278
- Testing
- rituximab, fludarabine phosphate, melphalan
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- City of Hope Medical Center
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
This pilot phase II trial studies how well a new reduced intensity conditioning regimen that includes haploidentical donor NK cells followed by the infusion of selectively T-cell depleted progenitor cell grafts work in treating…
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myelogenous Leukemia (CML)
- Trial name
- NCT02259348
- Testing
- Cyclophosphamide, Fludarabine, G-CSF
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- St. Jude Children's Research Hospital
Leukemia
A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL
RATIONALE: Monoclonal antibodies, such as alemtuzumab and rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00858117
- Testing
- Alemtuzumab, Rituximab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University
ALL, Childhood, Lymphoblastic Lymphoma, Childhood
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
This is a phase 1/2 study of a drug called Ixazomib in combination with cytotoxic chemotherapy consisting of Vincristine, Dexamethasone, Asparaginase, and Doxorubicin (VXLD).
- Conditions
- ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood
- Trial name
- NCT03817320
- Testing
- Ixazomib, Vincristine, Dexamethasone
- Where
- 18 sites in United States, Australia
- Volunteers
- 24 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.